# I-SABR (NCT03110978)

> Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03110978
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Lung Atypical Carcinoid Tumor; Lung Neuroendocrine Neoplasm; Lung Non-Small Cell Squamous Carcinoma; Minimally Invasive Lung Adenocarcinoma; Neuroendocrine Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Large Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8
- Interventions: Nivolumab; Stereotactic Body Radiation Therapy
- Enrollment: 140
- Primary outcome: Event-free survival with events defined as local recurrence, regional recurrence, distant metastasis, secondary malignancy (including lung cancer), and death

## Indexed commentary on I-SABR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=i-sabr-nct03110978